|
US2020131137A1
|
|
Continuous process for the preparation of 2-(1H-imidazol-4-yl) ethanamine and pharmaceutically acceptable salts thereof
|
|
AU2019337115A1
|
|
Pharmaceutical compositions of sulfur colloid and processes thereof
|
|
WO2020049536A1
|
|
Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
|
|
WO2020012406A1
|
|
Veterinary dosage forms
|
|
WO2019058354A1
|
|
Eslicarbazepine suspension
|
|
WO2019058353A1
|
|
Modified release suspension of eslicarbazepine
|
|
CN110545818A
|
|
Lamotrigine suspension formulations
|
|
WO2019008594A1
|
|
Continuous process for the preparation of 2-(1h-imidazol-4-yl) ethanamine and pharmaceutically acceptable salts thereof
|
|
AU2017339246A1
|
|
Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
|
|
AU2017339247A1
|
|
Pharmaceutical suspension dosage form of benzimidazole compounds and process of preparation thereof
|
|
WO2018007956A1
|
|
Immediate release pharmaceutical composition of iron chelating agents
|
|
WO2017216661A1
|
|
Process for the preparation of brexpiprazole from 7-(4-chlorobutoxy)quinolin-2(1h)-one and 1-(benzo[b]thiophen-4-yl)piperazine
|
|
WO2017195144A1
|
|
Pharmaceutical compositions comprising brivaracetam
|
|
EP3402488A1
|
|
Solid oral dosage forms of eslicarbazepine
|
|
WO2016193880A1
|
|
Immediate release pharmaceutical composition of tizanidine
|
|
WO2016139681A2
|
|
Pharmaceutical composition of tizanidine and process for preparing the same
|
|
WO2016139683A2
|
|
Pharmaceutical compositions of lurasidone and process for preparing the same
|
|
US2017313699A1
|
|
Process for the preparation of apixaban and intermediates thereof
|
|
US2017246165A1
|
|
Process for the preparation of Lurasidone hydrochloride
|
|
EP3013324A1
|
|
Disintegrant free composition of cinacalcet
|
